Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

530
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
530
Signs of Puberty01:27

Signs of Puberty

562
Puberty is a critical phase, typically beginning between the ages of 8 and 13 in girls and 9 and 14 in boys, though timing can vary based on genetics, environmental factors, and overall health. This period is characterized by the development of secondary sexual characteristics and the attainment of reproductive potential. Endocrine changes underpin puberty, with hormonal surges of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) instigated by Gonadotropin-Releasing Hormone (GnRH)...
562
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

231
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
231
Factors Affecting Drug Distribution: Physiological Barriers01:23

Factors Affecting Drug Distribution: Physiological Barriers

294
Drug distribution in the body is intricately regulated by various physiological barriers that control the passage of substances. These include the capillary endothelial barrier, the blood-brain, blood-cerebrospinal fluid, blood-placental, and blood-testis barriers.
The capillary endothelial barrier allows only smaller molecules below 600 Da (Daltons) to pass through. It also restricts drugs like heparin that are bound to blood components, limiting their movement within the bloodstream.
The...
294
Infertility in Males01:23

Infertility in Males

316
Male infertility affects millions of couples worldwide, arising from various factors that impact different stages of the reproductive process. An endocrine imbalance resulting from conditions like hypogonadism, Klinefelter syndrome, or pituitary disorders can disrupt hormone levels and reduce sperm production. Testicular defects, such as tumors, cryptorchidism, atrophic testes, abnormal sperm morphology, and low sperm count or motility, may arise due to genetic factors, structural...
316
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

353
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
353

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Updated compendium of genes and variants associated with congenital hypogonadotropic hypogonadism: systematic review, classification pipeline, and network analysis.

Human molecular genetics·2026
Same author

46,XY DSD with Partial Gonadal Dysgenesis and Growth Failure in a Patient with 3q27.1 Microdeletion: Candidate Gene Curation After Exhaustive Literature Review.

International journal of molecular sciences·2026
Same author

A Novel POR G88S Mutation Causes Severe PORD and Establishes a Critical Pharmacogenomic Risk Profile.

The Journal of clinical endocrinology and metabolism·2025
Same author

Gonadal Function and Its Evolution in 46,XX Testicular/Ovotesticular DSD.

The Journal of clinical endocrinology and metabolism·2025
Same author

EndoCompass project: research roadmap for reproductive and developmental endocrinology.

European journal of endocrinology·2025
Same author

Differences of sex development.

Nature reviews. Disease primers·2025

Related Experiment Video

Updated: Aug 24, 2025

Determination of Reproductive Competence by Confirming Pubertal Onset and Performing a Fertility Assay in Mice and Rats
06:38

Determination of Reproductive Competence by Confirming Pubertal Onset and Performing a Fertility Assay in Mice and Rats

Published on: October 13, 2018

15.6K

Considerations when treating male pubertal delay pharmacologically.

Rodolfo A Rey1,2

  • 1Centro de Investigaciones Endocrinológicas "Dr. César Bergadá" (CEDIE), CONICET - FEI - División de Endocrinología, Hospital de Niños Ricardo Gutiérrez, Buenos Aires, Argentina.

Expert Opinion on Pharmacotherapy
|October 20, 2022
PubMed
Summary
This summary is machine-generated.

Delayed puberty in males can cause psychosocial distress. Early diagnosis and timely hormone replacement therapy, including testosterone or aromatase inhibitors, are crucial for optimal outcomes.

Keywords:
Aromatase inhibitorconstitutional delay of growth and puberty (CDGP)gonadotrophin-releasing hormone (GnRH)human chorionic gonadotrophin (hCG)hypergonadotrophic hypogonadismhypogonadotrophic hypogonadismletrozolerecombinant follicle-stimulating hormone (r-FSH)testosterone enanthatetestosterone undecanoate

More Related Videos

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing
05:25

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing

Published on: August 14, 2019

19.3K
Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies
06:24

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Published on: January 10, 2025

888

Related Experiment Videos

Last Updated: Aug 24, 2025

Determination of Reproductive Competence by Confirming Pubertal Onset and Performing a Fertility Assay in Mice and Rats
06:38

Determination of Reproductive Competence by Confirming Pubertal Onset and Performing a Fertility Assay in Mice and Rats

Published on: October 13, 2018

15.6K
Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing
05:25

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing

Published on: August 14, 2019

19.3K
Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies
06:24

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Published on: January 10, 2025

888

Area of Science:

  • Pediatric Endocrinology
  • Male Reproductive Health

Background:

  • Delayed puberty in males significantly impacts psychosocial well-being, raising concerns about genital development and stature.
  • While often transient, delayed puberty necessitates ruling out underlying medical conditions.

Approach:

  • This review discusses the etiologies of delayed puberty in males and their pharmacological treatment options.
  • It examines current practices, acknowledging the scarcity of high-quality evidence and reliance on case series.

Key Points:

  • Watchful waiting is suitable for suspected constitutional delay of growth and puberty (CGDP) in 12-14 year olds.
  • Hormone replacement is recommended by age 14 for delayed puberty and by age 12 for diagnosed hypogonadism.
  • Testosterone therapy is standard, with aromatase inhibitors as an emerging alternative; gonadotropin therapy shows promise for central hypogonadism.

Conclusions:

  • Timely medical intervention for delayed puberty in males is essential to mitigate psychosocial distress.
  • Established therapies like testosterone are effective, while newer options like aromatase inhibitors and gonadotropins require further research for optimal application.